|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||14.28 - 14.77|
|52-week range||8.31 - 18.65|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||N/A|
Yup! Things seem to be looking up for Valeant Pharmaceuticals International (VRX). The drug maker reported third quarter per-share profit that blew past expectations, albeit lowered expectations. Moody’s ...
Valeant Pharmaceuticals International Inc. has been directed by the Securities and Exchange Commission to clean up its use of nonstandard numbers, but the company is now sending one number to reporters ...
Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that reassure investor that it was making progresses rebuilding itself after following a series of investigations into the drug maker’s accounting and pricing practices. Also helping fuel the upswing, Valeant reduced its total debt by $6 billion since the first quarter of 2016. Today, the shares are pulling back following Valeant’s launch of a $750 million debt offering.
Valeant Pharmaceuticals International Inc. said Monday it was launching a private offering of $750 million worth of notes due 2025, paying 5.500%. The drug maker plans to use the proceeds from the debt ...
Short selling is not a dark art performed by ‘angry contrarians,’ but provides an opportunity for ‘financial protesters’ to potentially profit without having to always bet in one direction.
It’s been a big week for Valeant Pharmaceuticals International (VRX). The troubled drug maker released estimate-beating third quarter financial results earlier this week that had many, even some of the biggest bears on the stock, commending the headway Valeant has made in streaming the company, fixing its balance sheet and getting new drugs approved. Shares of Valeant have surged almost 31% over the past five days.
Nov 10 (Reuters) - Valeant Pharmaceuticals International Inc : * Valeant Pharmaceuticals completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I, L.P. ...
Wall Street bears are sounding alarms about a recent drop in non-investment-grade bonds, popularly referred to as junk bonds.
Are things looking up for Valeant Pharmaceuticals International (VRX)? The outlook for the drug maker’s debt seems to be improving, at least according to Moody’s Investors Services. The ratings firm did not change Valeant’s credit rating (the corporate family ratings is B3 and the senior unsecured notes are at Caa1), but it did lift its outlook from negative to stable on the heels of an estimate-beating earnings report unveiled earlier this week.
The much-maligned drugmaker is making progress, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning a key FDA approval.
Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares nearly 6% on the day amid huge volumes.
Shares of Valeant Pharmaceutical International (VRX) continued to climb today on the heels of yesterday’s estimate-beating earnings report. The shares spiked more than 6.8% today to just under $15 a share. Deutsche Bank analyst Gregg Gilbert concedes that Valeant is making “more progress” in rebuilding itself and regaining investors’ confidence following a series of investigations into the drug maker’s accounting and pricing practices.
Third-quarter financials ignited a sharp rally in the company's stock, but there are a couple of lingering question marks every investor ought to know about.
The Dow Jones Industrial Average eked out a fourth consecutive record high close on Tuesday, while the S&P 500 ended marginally lower after a disappointing profit forecast from Priceline and a drop in ...
Wall Street dipped on Tuesday after a disappointing profit forecast from Priceline and as investors fretted that a Republican plan to cut corporate taxes could be watered down. The S&P 500 financial index ...
TALLAHASSEE, Fla. (AP) — Florida's state-run pension plan is going to sue a pharmaceutical company over millions in losses that top officials contend were due to fraud.